# Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC

> **NCT06881823** · PHASE1,PHASE2 · WITHDRAWN · sponsor: **Novartis Pharmaceuticals**

## Conditions studied

- Prostate Cancer

## Interventions

- **DRUG:** AAA602
- **DRUG:** AAA802
- **DRUG:** Gallium (68Ga) gozetotide
- **DRUG:** Piflufolastat (18F)
- **DRUG:** Flotufolastat F 18
- **DRUG:** 18F-PSMA-1007

## Key facts

- **NCT ID:** NCT06881823
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2026-06-29
- **Primary completion:** 2030-03-31
- **Final completion:** 2033-06-01
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** The radioligands to be evaluated showed acceptable safety but limited benefit in metastatic prostate cancer
- **Last updated:** 2025-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06881823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06881823, "Study to Assess [177Lu]Lu-PSMA-R2 (AAA602) and [225Ac]Ac-PSMA-R2 (AAA802) in Participants With PSMA-positive HRLPC". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06881823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*